take rout innov solut growth tp
maintain hold rate downgrad
tp deriv estim base
forward price-to-earnings multipl adjust ep
give upsid potenti
expect top-lin revenu declin
estim base follow factor
acquisit made strengthen busi
biosimilar gener impact
johnson johnson sale increas
increas also
estim
ep adjust
ep increas increas
adjust ep
estim
world-wide consum sale increas
increas due growth over-the-
counter product includ tylenol motrin analges
digest health product neutrogena ogx
beauti product listerin oral care product
mn except ep crispidea namejohnson johnson tickerjnjstock ratingholdunchangedindustri viewoverweightpositivepric week week volum volum ep gin gin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispideaakansha johnson johnson| ch
incom statement
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
world-wide pharmaceut sale increas
sale includ impact actelion ltd
contribut world-wide oper sale
growth increas driven stelara
common stock announc
complet acquisit ci hold co ltd
market dr ci labo labo labo genom
line skincar product
quarter food drug administr
fda approv addit indic invokana
canagliflozin reduc risk major advers
enter world-wide collabor licens
agreement argenx bvba argenx se develop
commerci cusatuzumab investig
therapeut antibodi target
current price-to-earnings averag price-to-earnings
due decreas stock price price-to-earnings
volatil past due volatil stock
price movement trend ep price-to-earnings increas
due increas stock price price-to-earnings trail
expect forward price-to-earnings
recommend hold rate expect
declin revenu due competit
pharmaceut product expect declin
revenu increas
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date ex-dividend date feb last split factor new per last split date jun inform johnson johnson| ch
incom statement
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total gross research sale gener restructur merger oper total oper oper interest incom incom provis incom net incom avail common ep ep weight averag share estim annual actual quarterli actual annual johnson johnson| march
 market account receivable- total prepaid current assets- total current build machineri furnitur total fix non-curr defer incom non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in capital- retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item johnson johnson| march
flow oper result net earn non-
cash expens adjust depreci amort stock-bas compens
invest activ use addit properti plant equip net
purchas invest market secur acquisit net cash acquir
primarili acquisit zarbe use
financ activ use dividend sharehold repurchas
common stock net retir short long-term debt financ
depreciation- defer incom oper increas decreas increas decreas current assets- decreas increas payables- decreas increas current liabilities- decreas increas work non- items- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end johnson johnson| march
deliv anoth quarter strong oper sale growth
oper profit grew quarter
johnson johnson sale increas compar
oper sale result increas
neg impact currenc domest sale increas
sale increas reflect oper growth
neg currenc impact exclud net impact
acquisit divestitur oper basi world-wide sale
increas domest sale increas intern
sale increas
total revenu increas
compar total intern revenu increas
compar
billion
sale europ flat sale
hemispher exclud declin
sale compani asia-pacif africa region grew
cog decreas compar
cog revenu decreas compar
increas
compar
total revenu
 increas
compar
gross profit increas compar
sg expens decreas compar
sg expens revenu declin
compar
 expens decreas compar
 sale decreas
compar
interest expens net compar
expens net compar
incom net restructur expens declin
compar
oper profit increas compar
adjust oper profit increas
compar
effect tax rate compar
non-gaap tax rate compar
gaap net earn declin compar net loss
includ after-tax intang amort expens
net charg after-tax special item non-gaap net
earn increas compar
gaap ep compar non-gaap
ep compar
sg expens
revenu declin
compar
gaap ep
compar
non-gaap ep
compar
deliv anoth year strong oper sale growth
achiev adjust oper earn growth
world-wide sale increas compar
oper result increas posit
impact currenc domest sale increas
sale increas reflect oper growth
posit currenc impact
exclud net impact acquisit divestitur oper
basi world-wide sale increas domest sale increas
intern sale increas
sale increas compar
sale increas compar
sale compani europ achiev growth compar
includ oper growth posit currenc impact
sale compani western hemispher exclud
achiev growth compar includ oper growth
neg currenc impact
sale compani asia-pacif africa region achiev growth
compar includ oper growth
posit currenc impact
increas
compar
sale compani
asia-pacif africa
compar
billion
cog increas compar
cog sale decreas compar
decreas due lower inventori step-up cost relat
actelion acquisit favor product segment mix driven higher
percentag sale segment
gross profit increas compar
sg expens increas compar
sg sale declin compar
due lower cost rel sale growth
busi favor segment mix
 expens increas compar
 sale decreas compar
in-process expens compar
interest expens net compar due
higher averag debt balanc expens net
compar incom restructur expens
compar
oper profit increas compar
effect tax rate compar
adjust tax rate compar
net earn increas compar
adjust net earn increas compar
gaap ep increas compar non
gaap ep increas compar
compar
compar
divid major segment consum segment
medic devic segment contribut sale
consum segment contribut sale medic devic segment
contribut
total revenu consum segment increas
compar total revenu
compar growth driven
premium beauti strong over-the-counter consumpt
total revenu increas
compar total intern revenu decreas
compar
world-wide oper result exclud net impact acquisit
divestitur driven growth over-the-count product includ
tylenol motrin analges digest health product neutrogena
ogx beauti product listerin oral care product
subsequ quarter compani announc complet
acquisit ci hold co ltd market dr ci labo labo
labo genom line skincar product
sale
contribut sale
medic devic
total revenu
increas
compar
world-wide revenu
beauti product
increas
compar
world-wide revenu
increas
compar
due new
world-wide revenu beauti product increas
compar total revenu increas
compar
total revenu increas compar
total intern revenu increas
compar
growth driven neutrogena ogx aveeno product
well strength dr ci labo dabao product outsid
world-wide revenu oral product increas
compar due new product launch
total revenu increas compar
total revenu increas
compar total intern revenu declin
compar
world-wide revenu
compar
world-wide revenu over-the-counter product increas
compar total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
growth driven share consumpt market growth across
multipl brand includ zyrtec tylenol children motrin
well digest health product anti-smok aid addit sale
recent acquisit zarbe inc contribut growth
world-wide revenu women health product decreas
compar total revenu
declin compar
growth latin america off-set neg impact currenc
total revenu increas compar
total intern revenu declin
compar
world-wide revenu babi product declin
compar total revenu declin
compar declin due
johnson share declin increas trade promot due
johnson babi relaunch neg impact currenc
world-wide revenu
babi product
declin
compar
total revenu decreas compar
total intern revenu decreas
compar
world-wide revenu wound product decreas
compar total revenu
decreas compar due
divestitur compe
total revenu increas
compar total intern revenu declin
compar
world-wide revenu
decreas
compar
pharmaceut
segment increas
compar
world-wide revenu pharmaceut segment increas
compar total revenu
increas compar
total revenu increas compar
total intern revenu increas
compar
world-wide immunolog revenu increas
compar total revenu increas
compar
total immunolog revenu increas
compar total intern revenu increas
compar
growth driven strong uptak stelara crohn diseas strong
launch uptak tremfya expand indic simponi/simponi
aria golimumab immunolog market growth immunolog
neg impact lower sale remicad infliximab due
increas discounts/reb biosimilar competit
simponi/simponi aria revenu decreas
compar total revenu increas
compar total revenu
 increas total intern revenu
increas
stelara revenu increas compar
total revenu increas
compar total revenu increas
total intern revenu increas
remicad revenu declin compar
total revenu decreas
compar total revenu declin
revenu export declin
total intern revenu decreas
revenu increas
compar
declin
compar
cardiovascular
decreas
compar
decreas
compar
tremfya revenu compar
total revenu compar
world-wide revenu cardiovascular decreas
compar total revenu declin
compar
total cardiovascular revenu declin
compar total intern revenu decreas
compar
lower sale invokana/invokamet due increas
price discount higher rebat market share declin driven competit
pressur lower sale xarelto rivaroxaban driven increas
discount rebat partial off-set increas market share
xarelto revenu decreas compar
total revenu decreas
compar
invokana invokamet revenu decreas
compar total revenu declin
compar total revenu
 declin total intern revenu
increas
procrit eprex revenu declin
compar total revenu increas
compar total revenu
 decreas total intern revenu
increas
revenu declin compar
total revenu declin
compar
world-wide revenu oncolog increas
compar total revenu increas
compar
total oncolog revenu increas
compar total intern revenu increas
compar
growth due strong sale darzalex continu market
growth share gain imbruvica due increas patient uptak global
sale zytiga driven latitud data market growth sale
launch erleada contribut growth
darzalex revenu increas compar
total revenu increas
compar total revenu increas
total intern revenu
imbruvica revenu increas compar
total revenu increas
compar total revenu increas
total intern revenu increas
zytiga revenu increas compar
total revenu increas
compar total revenu increas
total intern revenu increas
oncolog increas
compar
increas
compar
world-wide revenu
increas
compar
velcad revenu decreas compar
total revenu increas
compar
oncolog increas compar
total intern revenu increas
compar
increas
compar
world-wide revenu pulmonari hypertens increas
compar total revenu
increas compar
total revenu increas compar
total intern revenu increas
compar
sale opsumit uptravi posit impact market growth
share gain sale tracleer neg impact
increas use opsumit gener
opsumit revenu increas compar
total revenu increas
compar total revenu increas
total intern revenu increas
tracleer revenu decreas compar
total revenu increas
compar total revenu
increas total intern revenu increas
world-wide revenu
product increas
compar
uptravi revenu increas compar
total revenu increas
compar total revenu increas
total intern revenu increas
revenu declin compar
total revenu increas
compar
increas
compar
world-wide revenu infecti diseas product increas
compar total revenu
increas compar
total revenu increas
compar total intern revenu increas
compar
sale growth prezcobix/rezolsta edurant/rilpivirin launch
symtuza juluca partial off-set lower sale
edur revenu increas compar
total revenu increas
compar total revenu flat
total intern revenu increas
prezista prezcobix rezolsta symtuza increas
compar total revenu increas
compar total revenu
 increas total intern
revenu increas
neurosci
product decreas
compar
infecti diseas decreas
compar total revenu decreas
compar total revenu
 declin total intern revenu
declin
increas
compar
world-wide revenu neurosci product decreas
compar total revenu
increas compar
total revenu decreas
compar total intern revenu decreas
compar
strong sale long-act inject invega trinza/trevicta
invega sustenna/xeplion partial off-set cannib
risperd consta gener competit concerta
invega sustenna xeplion trinza trevicta revenu increas
compar total
revenu increas compar
total revenu increas
total intern revenu increas
concerta methylphenid revenu decreas
compar total revenu decreas
compar total revenu
 decreas total intern
revenu increas
medic devic
segment decreas
compar
risperd consta revenu declin
compar total revenu decreas
compar total revenu
 declin compar
total intern revenu declin
intervent
solut increas
compar
world-wide revenu medic devic segment decreas
compar total revenu
increas compar
total revenu increas
compar total intern revenu increas
compar
world-wide revenu intervent solut increas
compar total revenu
increas compar
total revenu increas
compar total intern revenu increas
compar
orthoped
decreas
compar
intervent solut franchis includ cerenovu busi
previous includ spine orthopaed sale led
strong growth electrophysiolog busi driven atrial
fibril procedur growth continu uptak thermocool
total revenu hip
product increas
compar
world-wide revenu orthoped decreas
compar total revenu decreas
compar
total revenu decreas
compar total intern revenu decreas
compar
total revenu hip product increas
compar total revenu increas
compar total revenu
 increas total intern revenu
increas
total revenu knee product decreas
compar total revenu decreas
compar total revenu
 decreas total intern revenu
increas
total revenu
increas
compar
revenu increas
compar
total revenu trauma product increas
compar total revenu increas
compar total revenu
increas total intern revenu increas
total revenu spine product declin
compar total revenu declin
compar total revenu
declin total intern revenu declin
world-wide revenu surgic product increas
compar total revenu increas
compar
total revenu increas compar
total intern revenu increas
compar
advanc surgeri revenu increas
compar total revenu
compar total revenu increas
total intern revenu increas
gener surgeri revenu increas
compar total revenu increas
compar total revenu
 increas total intern revenu
increas
specialti surgeri revenu increas
compar total revenu increas
compar total revenu
 declin total intern revenu
increas
revenu increas
compar
growth advanc surgeri driven endocutt biosurgeri
energi product growth gener surgeri driven wound care
product growth specialti surgeri driven advanc steril
increas
compar
total revenu vision care product increas
compar total revenu increas
compar total revenu
 increas total intern
revenu increas
contact lens revenu increas compar
total revenu increas
compar total revenu increas
total intern revenu increas
surgic revenu increas compar
total revenu increas
compar total revenu increas
total intern revenu increas
growth driven strength astigmat daili dispos
lens oasi contact lens categori surgic growth cataract
perform primarili outsid
share repurchas program jnj common stock
research studi
enter
research studi enter collabor inc help
collabor appl
inc help improv
complet acquisit ci hold co ltd market
dr ci labo labo labo genom line skincar product
complet divestitur global roc skincar portfolio product
collabor licens
agreement enter
argenx
develop
first patient enrol stellar investig devic exempt
studi evalu safeti effect heliostar multi-
electrod radiofrequ balloon ablat cathet treat symptomat
excel registri launch collect analyz stroke-induc
blood clot remov brain embotrap ii revascular
 fda approv invokana canagliflozin reduc risk major
advers cardiovascular cv event includ heart attack stroke death due
cardiovascular caus adult type diabet
type ii variat submit european medicin agenc
ema imbruvica ibrutinib combin obinutuzumab
previous untreat adult chronic lymphocyt leukemia
combin rituximab treatment previous untreat
relapsed/refractori adult waldenstrm macroglobulinemia
world-wide collabor licens agreement enter
argenx develop commerci cusatuzumab
investig therapeut antibodi target
clinic data present eclips studi demonstr
tremfya superior cosentyx treat adult moder
sever plaqu psoriasi primari endpoint assess week
supplement biolog licens applic submit fda
group type ii variat applic submit ema seek approv
stelara treatment adult moder sever activ
european commiss ec grant market split-dos regimen
darzalex daratumumab two consecut day
supplement new drug applic submit fda xarelto
rivaroxaban prevent venou thromboembol medic ill
complet divestitur sylvant siltuximab treatment
ec grant market author erleada apalutamid non-
metastat castration-resist patient high risk develop
complet respons letter receiv fda snda opsumit
treatment adult inoper chronic thromboembol pulmonari
drug applic
submit fda
prevent
thromboembol
deal make heat medical-technolog industri devic
maker hunt innov product boost growth surgic instrument
busi expect reach biggest
player space includ
decemb medtron plc complet deal acquir mazor robot
ltd isra compani whose robotics-assist product aid spine brain
johnson johnson work disrupt medic innov
announc februari subsidiari ethicon inc enter
definit agreement acquir auri health inc cash
addit conting payment aggreg may
acquisit help develop digit tool diagnosi early-stag
intervent lung cancer area compani increasingli
focus auriss tool could allow lung cancer caught earlier
abl reach lung conduct minim invas biopsi
health-car giant explor option treat earlier-stag lung cancer
tool
addit advanc compani focus initi combat lung
cancer auri health technolog support johnson johnson vision
world leader across continuum surgic approach includ
open laparoscop robot endolumin
sale js medic devic unit recov sinc turnaround
effort began compani expect unit achiev above-
market growth would expect move aggress
robot field gap medic devic busi
johnson johnson announc ethicon inc enter definit
agreement acquir auri health inc cash addit
conting payment aggreg may payabl upon
auri health privat held develop robot technolog initi
focus lung cancer fda-clear platform current use
bronchoscop diagnost therapeut procedur
auri part js medical-devic divis world largest maker
health-car product also robotic-surgeri compani call verb
surgic inc form verili life scienc part googl parent
alphabet inc late
auri found surgic robot pioneer freder moll join
johnson johnson upon complet transact close subject
anti-trust clearanc customari close condit transact
expect close end compani discuss
transact next quarterli earn call april
auriss flagship product robot use surgeon via control direct
scope patient bodi camera devic call monarch
approv regul last year diagnost therapeut
bronchoscop procedur instrument insert nose
auri health current focu lung cancer monarch platform robot
technolog play import role within lung cancer initi
johnson johnson enabl develop differenti digit
solut address key step lung cancer care journey diagnosi
earli stage intervent central jnj commit develop
solut prevent intercept cure deadli diseas
transact also complementari acquisit orthotaxi
robot technolog orthoped continu develop verb
surgic platform strateg partnership verili acquisit
acceler johnson johnson entri robot potenti
growth expans intervent applic
 js share margin midday trade intuit
surgic fell much analyst said auri could becom
formid competitor given js commerci scale js stock gain
past year compar growth record industri
new era health care aim simplifi surgeri drive effici
reduc complic improv outcom patient ultim make
surgeri safer collect technolog togeth market-lead
medic implant solut creat foundat comprehens
digit ecosystem help support surgeon patient
surgeri
revenu
expect
rang
adjust ep expect
rang
revenu expect rang
effect tax rate expect rang
adjust ep expect rang
net interest expens expect rang
strong core busi
across enterpris
strong core busi platforms/product across enterpris
acceler growth medic devic improv execut new
uptak new product erleada tremfya
potenti nme key line extens file approv
loss exclusivity/generics/biosimilar remicad velcad procrit
acceler growth
medic devic
improv execut
year strong
achiev
consecut year
earn growth
deliv anoth year strong oper sale growth
achiev consecut year adjust oper earn growth
world-wide consum sale increas increas
due growth over-the-count product includ tylenol
motrin analges digest health product neutrogena ogx
beauti product listerin oral care product
world-wide pharmaceut sale increas sale
includ impact actelion ltd contribut world-wide
oper sale growth increas driven stelara ustekinumab
simponi/simponi aria zytiga darzalex daratumumab imbruvica
androgen receptor inhibitor treatment adult patient non-
metastat castration-resist prostat cancer nmcrpc high risk
world-wide medic devic sale increas sale
includ impact divestitur lifescan busi neg
impact world-wide oper sale growth
medic devic segment revenu increas due growth
electrophysiolog product intervent solut busi acuvu
contact lens surgic product vision busi wound closur
product gener surgeri busi along endo-cutt bio-
surgic advanc surgeri busi
jnj strength broad base busi disciplin approach portfolio
manag posit compani continu fuel invest
innov enabl capit strateg opportun deliv
strong perform long-term
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
y/i revenu growth compar
gross margin compar
oper margin compar
net margin compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth johnson johnson| march
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale johnson johnson| march
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset johnson johnson| march
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item johnson johnson| march
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free johnson johnson| march
current price-to-earnings averag price-to-earnings due decreas stock price price-to-earnings
volatil past due volatil stock price movement trend ep
price-to-earnings increas due increas stock price price-to-earnings trail
expect forward price-to-earnings
incom statement
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc state mutual automobil insur northern trust geod capit manag massachusett servic america capit world top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf vanguard institut fund-institut fidel ishar washington mutual investor vanguard -valu mf seri trust i-mf valu select sector spdr fund-health johnson johnson| march
developmentsjanssen announc fda approv spravatotm esketamin ciii nasal spray adult treatment-resist depress trd cycl multipl treatment without reliefmarch janssen compani johnson johnson announc food drug administr fda approv spravato esketamin ciii nasal spray use conjunct oral antidepress adult treatment-resist depress trd johnson johnson announc agreement acquir auri inc februari creat next frontier surgeri johnson johnsonannounc thatethicon inc enter definit agreement acquireauri inc cash addit conting payment aggreg may payabl upon reach certain predetermin mileston auri privat held develop robot technolog initi focus lung cancer anfda-clear platform current use bronchoscop diagnost therapeut procedur acquisit acceleratejohnson johnson sentri robot potenti growth expans intervent applic janssen enter world-wide collabor licens agreement meiragtx develop gene therapi program inherit retin diseasesjanuari janssen compani johnson johnson announc world-wide collabor licens agreement plc clinical-stag gene therapi compani develop manufactur commerci clinic stage inherit retin diseas portfolio includ lead product candid achromatopsia achm caus mutat either x-link retin pigmentosa xlrp compani form research collabor explor new target inherit retin diseas develop adeno-associ viru aav manufactur technolog johnson johnson announc research studi appl watch help improv afib outcom includ stroke preventionjanuari johnsonannounc thatjanssen inc member johnson johnson famili compani enter research studi collabor withappl inc investig whether new heart health program use app fromjohnson johnsonin combin appl watch irregular rhythm notif ecg app acceler diagnosi improv health outcom peopl world-wide live atrial fibril afib condit lead stroke potentiallydevast complic alon afibi respons approxim death hospit everi year johnson johnson| march
incom statement
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
perform
compar
roa roi roe
ttm basi
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit consensu view analyst trend stock
forecast expect
forward price-to-earnings
higher
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonjnjindustri avg avgprice/earn yield johnson johnson| march
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr johnson johnson| march
incom statement
non-
per share item
balanc sheet item
product perform develop
valuat consensu perform
stock price dip decemb due uncertainti regard product sinc
volatil
stock declin averag volum trade share
stock price volatil year huge dip decemb
stock gave return past rang stock
stock price show upward trend
surg novemb stock given return past
recommend hold rate tp estim adjust ep
estim declin revenu deliv strong perform
due market growth across busi expect top-lin revenu grow
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host ofclient
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com orcontact
